Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are anticipating strong growth driven by the robust sales of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential pressures from